Representatives from biotech, academia, patient advocacy, and the investor community will have a robust and interactive discussion about next generation therapies to treat blinding eye diseases that affect the retina and cornea - the current treatment landscape, what’s working, and what’s next. Additionally, attendees will walk away with a better understanding of the patient and caregiver’s needs.